After more than six decades of Barbie, there's no question the beloved doll can do it all. She rocks different hairstyles, explores countless careers, and celebrates different backgrounds. Express yourself.And this week, doll maker Mattel is expanding her repertoire, introducing the first Barbie doll with type 1 diabetes. After past criticism over Barbie's early lack of diversity, Mattel says it marks an important step in our commitment to inclusivity and enables more children to see themselves reflected in ...

Oh, hey Barbie. There's a new girl on the block and she is not like any other doll on the market. This Barbie wears an adorable blue polka dot top, a ruffled minikirt, and an insulin pump.She is Mattel's first doll with type 1 diabetes. The doll was made in collaboration with a diabetes research organization to make sure all the accessories are accurate. ...

Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova’s Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial in Patients with Type 1 DiabetesLONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) to evaluate Eledon’s immunosuppressive agent tegoprubart (AT-1501) in Sernova’s ongoing Phase 1/2 clinical tria ...

Older patients taking GLP-1 drugs for diabetes face twice the risk of developing a serious eye disease, a new study says https://t.co/DHKsJVaF4m ...

GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to beco ...

MariTide Update Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our p ...

Core Insights - Amgen Inc announced full results from Part 1 of the Phase 2 study of MariTide, a long-acting peptide-antibody conjugate administered subcutaneously [1] Efficacy Results - In the Phase 2 study, MariTide demonstrated an average weight loss of approximately 20% in individuals with obesity without Type 2 diabetes (T2D), compared to 2.6% in the placebo group, and about 17% in individuals with obesity with T2D, compared to 1.4% in the placebo group [2] - Weight loss had not plateaued by 52 weeks, indicating potential for further reduction [2] - MariTide also showed a reduction in hemoglobin A1c (HbA1c) of up to 2.2% in obese and T2D patients [3] - Improvements were noted in cardiometabolic measures, including waist circumference, blood pressure, high-sensitivity C-reactive protein (hs-CRP), and select lipid parameters [4] Safety and Tolerability - No new safety signals were identified, and tolerability was consistent with the GLP-1 class, with gastrointestinal (GI) related adverse events being the most frequently reported, mostly mild to moderate [5] Study Progression - Complete results from the Phase 1 pharmacokinetics low dose initiation study were presented, showing an overall incidence of vomiting of 24.4% for one dose group and 22.5% for another, with no discontinuations due to GI adverse events [6][7] - The Phase 3 MARITIME program has been initiated, which is a 72-week chronic weight management study evaluating safety, efficacy, and tolerability in participants with obesity or overweight, with and without T2D [8] Future Studies - Amgen plans to initiate additional Phase 3 studies for atherosclerotic cardiovascular disease, heart failure, and obstructive sleep apnea in 2025 [9] Analyst Insights - Analysts express mixed views on the treatment policy estimand weight loss data, with some believing that reducing discontinuations through additional titration could yield Phase 3 results near 20% [9] - Questions remain regarding the potential for increased GI adverse events with expanded dosing intervals beyond every four weeks [10] Stock Performance - Following the announcement, Amgen's stock rose by 1.96% to $277.78 [10]

Core Insights - Lexicon Pharmaceuticals is set to present data on sotagliflozin's ability to reduce hypoglycemic events in type 1 diabetes patients at the 85th Scientific Sessions of the American Diabetes Association on June 22, 2025 [1][3] - The company will also present topline data from the PROGRESS Phase 2b study on pilavapadin (LX9211) for diabetic peripheral neuropathic pain during the same event [1][3] Sotagliflozin Presentation - The presentation titled "Sotagliflozin Added to Insulin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes Regardless of Kidney Function" will take place on June 22, 2025, from 4:00-4:15 p.m. CT [3] - Clinical efficacy data for sotagliflozin will be segmented by kidney function subgroups based on Estimated Glomerular Filtration Rate (eGFR) [2] PROGRESS Study Overview - The PROGRESS study began in December 2023, enrolling 496 adult patients with diabetes and moderate to severe diabetic peripheral neuropathic pain [6] - The study is placebo-controlled, focusing on changes in pain levels over an 8-week period with various dosages of pilavapadin [6][7] About Sotagliflozin - Sotagliflozin is an oral inhibitor targeting SGLT2 and SGLT1 proteins, which are involved in glucose regulation [5] - The drug has been studied in approximately 20,000 patients across various conditions, including heart failure and chronic kidney disease [5] About Diabetic Peripheral Neuropathic Pain (DPNP) - DPNP is a chronic complication of diabetes affecting around 9 million patients in the U.S., causing symptoms like burning pain and numbness [8]

Flash | 12 Jun 2025 08:08:06 ET │ 9 pages China Pharmaceuticals Catalysts ahead: Chinese companies in ADA 2025 CITI'S TAKE The American Diabetes Association (ADA) meeting (6/20-6/23; Chicago) will happen next week, and we summarize the expected presentations from the China companies due to attend. Innovent will likely present mazdutide DREAMS-1 Ph3 study for T2D and the preclinical data for the GLP-1/GIP/GCG/PCSK9 candidate. Oral GLP-1 data including ASC30 (Ph1a), HDM1002(Ph1b) and RGT-075 (Ph2a), as well a ...

Core Insights - Medtronic plc announced the name "MiniMed" for its planned new Diabetes Company, honoring its legacy and 40-year history in diabetes care [1] - The company aims to enhance diabetes management through innovative technology, making it more predictable and less burdensome for patients [1][2] - The separation of the Diabetes business is targeted for completion within 18 months, subject to legal and customary conditions [3] Company Overview - Medtronic is a global leader in healthcare technology, focusing on transforming diabetes care [1] - The Diabetes business employs over 8,000 individuals dedicated to innovation and improving health outcomes for diabetes patients [2] Historical Context - MiniMed was originally founded in 1983 by Alfred E. Mann, introducing groundbreaking innovations in diabetes care [1] - The name change reflects the company's commitment to its roots and the trust built over decades [1] Future Plans - The separation will involve capital markets transactions, potentially including a spin-off or split-off of the remaining shareholding in MiniMed [5] - The company is committed to fulfilling its mission of making diabetes management more stable and predictable [1][2]